TL;DR
Ascletis has submitted two IND applications to the U.S. FDA for new obesity treatments. The drugs include a once-monthly peptide injection and a co-formulation with GLP-1R/GIPR agonist. The development is still in early stages.
Ascletis has officially submitted two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for potential obesity treatments, signaling progress in its pipeline. The applications include a ASC36 once-monthly injection, a peptide amylin receptor agonist, and a co-formulation of ASC36_35, combining ASC36 with a peptide GLP-1R/GIPR agonist called ASC35. This move marks a key step toward clinical trials for these experimental therapies, which aim to address the growing global obesity crisis.
The first application pertains to ASC36, a once-monthly peptide injection designed to target receptors involved in appetite regulation. The second application involves ASC36_35, a co-formulation combining ASC36 with a GLP-1R/GIPR agonist intended to enhance efficacy through dual receptor targeting. According to Ascletis, these submissions are based on promising preclinical data suggesting potential benefits in weight management and metabolic regulation.
Ascletis, a biotechnology company headquartered in China, announced that the IND filings were made to facilitate Phase 1 clinical trials, which will evaluate safety, tolerability, and pharmacokinetics. The company stated that these developments are part of its broader strategy to develop innovative treatments for obesity, a condition affecting hundreds of millions worldwide.
While the IND applications have been submitted, it is not yet clear when the clinical trials will commence or the specific timelines for subsequent phases. The company emphasized that the FDA review process is ongoing, and further updates will follow once approvals are granted.
Potential Impact of Ascletis‘ Obesity Treatments in US Market
The submission of these IND applications indicates that Ascletis is progressing toward clinical testing of novel obesity therapies, which could diversify treatment options. If successful, these drugs may offer new mechanisms of action compared to existing options like GLP-1 receptor agonists, potentially improving efficacy or patient compliance. The move also highlights increased interest by biotech firms in developing innovative obesity treatments amid rising global health concerns and regulatory focus on metabolic diseases.
For patients, successful development could mean access to new once-monthly injectable options that may improve adherence and outcomes. For the industry, it underscores the competitive landscape in obesity therapeutics and the potential for new market entrants.
GLP-1 receptor agonist weight loss injections
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Ascletis’ Obesity Drug Development Timeline and Pipeline
Ascletis has been investing in metabolic and infectious disease research, with its pipeline including several candidates in various stages of development. The company’s focus on peptide-based therapies for obesity aligns with broader industry trends toward targeted, long-acting injectable drugs. Prior to these IND submissions, Ascletis reported positive preclinical data supporting the safety and efficacy of its compounds.
This is part of a wider movement within biotech to develop treatments that target multiple pathways involved in obesity and metabolic regulation, aiming to improve upon current therapies that often have limited efficacy or undesirable side effects. The IND filings are a critical step before human trials can begin, with regulatory review expected to take several months.
Historically, the FDA has shown interest in novel peptide and dual-receptor approaches, which could influence the approval process for these candidates.
„We are committed to advancing innovative treatments for obesity and are pleased to have submitted these IND applications to the FDA, marking an important milestone in our development pipeline.“
— Ascletis spokesperson
As an affiliate, we earn on qualifying purchases.
Uncertainties Surrounding Clinical Trial Timelines and Outcomes
It remains unclear when the FDA will approve the IND applications to proceed to human trials, as the review process can vary in duration. Additionally, the safety and efficacy of the compounds in humans are still unproven, and there is no guarantee of successful trial outcomes. Further, details about the specific design, sample size, or endpoints of the planned Phase 1 trials have not been disclosed.
amylin receptor agonist injectable
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Ascletis’ Obesity Drug Development Program
Ascletis will await FDA review and approval of its IND applications, which typically takes several months. Once approved, the company plans to initiate Phase 1 clinical trials to evaluate safety and pharmacokinetics. Positive results could lead to further development phases and eventual regulatory submissions for marketing approval. The company also indicated that it will continue to generate additional preclinical data to support ongoing development.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the main features of the drugs Ascletis is testing?
The drugs include a once-monthly peptide injection targeting appetite regulation and a co-formulation combining this peptide with a GLP-1R/GIPR agonist to enhance metabolic effects.
When will clinical trials likely start?
It depends on the FDA review process, but typically, IND approval can take several months. Ascletis has not yet announced specific trial start dates.
How do these drugs differ from existing obesity treatments?
These are designed as long-acting, once-monthly injections, potentially offering improved adherence. They also target multiple receptors involved in appetite and metabolic regulation, which may enhance efficacy.
What are the potential benefits if these drugs succeed?
If successful, they could provide new options with different mechanisms of action, possibly leading to better weight loss outcomes and improved quality of life for patients.
Source: primary
